Evidence map›Paper›PMID 42571571›Full record

ArticleClinical and translational radiation oncology2026

Stereotactic body radiotherapy for bone-only oligometastatic bladder Cancer: a multi-institutional experience.

Burak Tilki, Ozan Cem Guler, Birhan Demirhan, Pervin Hurmuz, Ayşenur Elmalı, Tolunay Kumru, Gokhan Ozyigit, Melek Yavuz, Cem Onal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Burak TilkiDepartment of Radiation Oncology, University of Health Sciences, Antalya City Hospital, Antalya, Turkiye.
Ozan Cem GulerDepartment of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, Turkiye.
Birhan DemirhanDivision of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkiye.
Pervin HurmuzDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkiye.
Ayşenur ElmalıDepartment of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkiye.
Tolunay KumruDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkiye.
Gokhan OzyigitDepartment of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkiye.
Melek YavuzDepartment of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkiye.
Cem OnalDepartment of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, Turkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate clinical outcomes, patterns of failure, local control (LC), and time to next systemic therapy (TTNT) in patients with bone-only oligometastatic bladder cancer treated with stereotactic body radiotherapy (SBRT). Materials and Methods: We retrospectively analyzed 26 patients with 41 bone metastases treated with SBRT between 2012 and 2020 across four institutions. All patients had ≤3 bone metastases and received metastasis-directed therapy to all lesions. Overall survival (OS), progression-free survival (PFS), TTNT, and LC were estimated using the Kaplan-Meier method. Results: After a median follow-up of 97.8 months, median OS was 8.9 months, with 1- and 2-year OS rates of 38.5% and 22.4%, respectively. Median PFS was 5.8 months, with 1- and 2-year PFS rates of 29.4% and 25.2%, respectively. Median TTNT was 4.4 months, and only 19.8% of patients remained free from systemic therapy at 1 year. Disease progression occurred in 46.2% of patients and was predominantly distant metastasis. In contrast, LC was excellent, with 1- and 2-year rates of 94.7% and 88.0%, respectively. No grade ≥ 3 toxicities were observed. Conclusion: SBRT achieved excellent LC with minimal toxicity. However, systemic progression remained common. These findings suggest that prospective studies are needed to determine the role of SBRT within multimodal treatment strategies for bone-only oligometastatic bladder cancer.

Indexed as

Bladder cancerBone metastasisMetastasis-directed therapyOligometastatic diseaseStereotactic body radiotherapy

Identifiers

PMID42571571
PMCPMC13452396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.